Accuray (ARAY) to Release Earnings on Wednesday

Accuray (NASDAQ:ARAY - Get Free Report) is expected to announce its Q3 2025 earnings results after the market closes on Wednesday, April 30th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $101.53 million for the quarter. Accuray has set its FY 2025 guidance at EPS.

Accuray (NASDAQ:ARAY - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.03. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. On average, analysts expect Accuray to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Accuray Price Performance

Shares of ARAY stock opened at $1.52 on Wednesday. The firm has a market cap of $156.30 million, a P/E ratio of -30.40 and a beta of 1.30. The firm has a fifty day moving average of $1.80 and a two-hundred day moving average of $1.95. The company has a debt-to-equity ratio of 3.51, a current ratio of 1.62 and a quick ratio of 0.88. Accuray has a 1-year low of $1.40 and a 1-year high of $2.95.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Accuray from a "hold" rating to a "buy" rating in a research note on Friday, April 11th.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.